0HQ1 Stock Chart & Stats
$33.51
$1.35(4.92%)
At close: 4:00 PM EDT
$33.51
$1.35(4.92%)
Day’s Range― - ―
52-Week Range$16.00 - $41.30
Previous CloseN/A
Volume60.00
Average Volume (3M)319.00
Market Cap
$1.47B
Enterprise Value$881.45
Total Cash (Recent Filing)$325.80M
Total Debt (Recent Filing)$53.97M
Price to Earnings (P/E)―
Beta1.33
Next Earnings
Nov 17, 2026EPS Estimate
0.16Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.75
Shares Outstanding43,808,390
10 Day Avg. Volume205
30 Day Avg. Volume319
Financial Highlights & Ratios
PEG Ratio0.39
Price to Book (P/B)0.76
Price to Sales (P/S)2.21
P/FCF Ratio34.28
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$35.00Price Target Upside4.45% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering3
EPS Forecast (FY)0.39
Revenue Forecast (FY)$600.44M
Bulls Say, Bears Say
Bulls Say
Recurring Revenue And Biorepository GrowthA large recurring revenue base improves visibility and customer retention, while biorepository utilization and consumables growth can support durable expansion beyond one-time instrument sales.
Conservative Balance SheetVery low leverage and substantial liquidity reduce refinancing risk and provide flexibility to fund research, operational improvements, acquisitions or customer deployments through uneven market conditions.
Improving Operating OutlookRaised guidance and sequential profitability improvement indicate that execution initiatives are beginning to stabilize performance, while growth in NGS, gene synthesis and sample management broadens the recovery opportunity.
Bears Say
Persistent UnprofitabilitySustained operating and net losses show that revenue has not yet translated into dependable earnings. This limits internally funded growth and leaves results sensitive to cost control, mix and execution.
Margin And Cash-Flow PressureLower gross margins, quality remediation and uneven working-capital conversion can constrain durable cash generation. UK Biocentre dilution and ongoing investments may further delay margin normalization.
CEO Leadership TransitionA sudden chief executive transition creates execution and strategic continuity risk while a permanent leader is selected. Although guidance was reaffirmed, leadership uncertainty can slow decisions and disrupt transformation efforts.
Azenta News
0HQ1 FAQ
What was Azenta’s price range in the past 12 months?
Azenta lowest share price was $16.00 and its highest was $41.30 in the past 12 months.
What is Azenta’s market cap?
Azenta’s market cap is $1.47B.
When is Azenta’s upcoming earnings report date?
Azenta’s upcoming earnings report date is Nov 17, 2026 which is in 81 days.
How were Azenta’s earnings last quarter?
Azenta released its earnings results on Aug 04, 2026. The company reported $0.16 earnings per share for the quarter, beating the consensus estimate of $0.114 by $0.046.
Is Azenta overvalued?
According to Wall Street analysts Azenta’s price is currently Undervalued.
Does Azenta pay dividends?
Azenta pays a Quarterly dividend of $0.1 which represents an annual dividend yield of N/A. See more information on Azenta dividends here
What is Azenta’s EPS estimate?
Azenta’s EPS estimate is 0.16.
How many shares outstanding does Azenta have?
Azenta has 43,808,390 shares outstanding.
What happened to Azenta’s price movement after its last earnings report?
Azenta reported an EPS of $0.16 in its last earnings report, beating expectations of $0.114. Following the earnings report the stock price went up 2.798%.
Which hedge fund is a major shareholder of Azenta?
Currently, no hedge funds are holding shares in GB:0HQ1
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Azenta Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$35.00 (4.45% Upside)
$35.00 (4.45% Upside)
Blogger Sentiment
Bullish
GB:0HQ1 Sentiment 75%
Sector Average ―
Sector Average ―
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-0.83%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-7.08%
Trailing 12-Months
Company Description
Azenta
Azenta, Inc. is a global leader specializing in advanced solutions for the discovery, handling, and preservation of life science samples. The company's operations span across North America, Europe, Asia Pacific (including China), and other international markets. Its business is structured into two main reportable segments: Life Sciences Products and Life Sciences Services. The Life Sciences Products division supplies sophisticated automated systems for the cold storage of chemical compounds and biological specimens. This segment also provides crucial equipment for sample preparation and manipulation, along with various consumables and specialized instruments that empower customers to effectively manage samples throughout their entire research and development workflows. Conversely, the Life Sciences Services segment offers a comprehensive suite of programs for sample management, integrated cold chain logistics, cutting-edge informatics, and a range of sample-centric laboratory services. These offerings are vital for propelling scientific research and accelerating drug development. Key services include secure sample banking, advanced genomic sequencing, gene synthesis, laboratory processing, detailed laboratory analysis, biospecimen acquisition, and other essential support functions. Azenta caters to a diverse client base within the life sciences sector, encompassing pharmaceutical companies, biotechnology firms, biorepositories, and academic or private research institutions. Established in 1978, the company, originally known as Brooks Automation, Inc., officially became Azenta, Inc. in December 2021. Its corporate headquarters are located in Chelmsford, Massachusetts.
0HQ1 Company Deck
0HQ1 Earnings Call
Q3 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call reflected a cautious but constructive tone: the company delivered a better-than-expected quarter with solid organic revenue growth (9%), sequential profitability improvement (adjusted EBITDA margin up ~610 bps sequentially) and progress on strategic initiatives (AI-enabled biorepository deployment, modular stores, UKBC integration, and B Medical divestiture). However, meaningful near-term headwinds remain — notably gross margin pressure (overall and in Sample Management Solutions), quality remediation costs ($5M–$6M expected), ongoing Sanger secular decline, negative quarterly free cash flow, and a difficult Q4 comp. Management emphasized disciplined execution and a measured outlook. Overall, positives around execution and a stronger outlook are balanced by persistent margin and demand uncertainties.View all GB:0HQ1 earnings summaries0HQ1 Stock 12 Month Forecast
Average Price Target
$35.00
▲(4.45% Upside)